2
Announcements
Trials
Browse
Landscape
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Observational
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Prostatic Neoplasms
195
Neoplasm Metastasis
22
Prostatic Neoplasms, Castration-Resistant
20
Breast Neoplasms
19
Neoplasms
18
Metastatic Castration Resistant Prostate Cancer
10
Prostate Cancer Metastatic
7
Metastatic Castration-Resistant Prostate Cancer
7
Triple Negative Breast Neoplasms
6
Metastatic Castration-resistant Prostate Cancer
6
Parkinson Disease 4, Autosomal Dominant Lewy Body
5
Pancreatic Neoplasms
5
Colorectal Neoplasms
5
Castration-resistant Prostate Cancer
5
Carcinoma, Non-Small-Cell Lung
5
Melanoma
4
Carcinoma, Hepatocellular
4
Bulbo-Spinal Atrophy, X-Linked
4
Adenocarcinoma
4
Urinary Bladder Neoplasms
3
Squamous Cell Carcinoma of Head and Neck
3
Small Cell Lung Carcinoma
3
Prostate Adenocarcinoma
3
Ovarian Neoplasms
3
Carcinoma, Renal Cell
3
mCRPC
2
Uterine Cervical Neoplasms
2
Recurrence
2
Prostatic Diseases
2
Non-metastatic Castration-resistant Prostate Cancer
2
Interventions
XENP 1595
2
Cancer Vaccines
2
Bevacizumab
2
Adjuvants, Immunologic
2
veliparib
1
glutathione pegylated liposomal doxorubicin
1
etoposide phosphate
1
enzalutamide
1
elacestrant
1
binimetinib
1
abemaciclib
1
Trastuzumab
1
Tissue Banks
1
Temozolomide
1
Radiotherapy
1
Radiosurgery
1
Radiation
1
RAD1901
1
Patient Discharge
1
PF-07284890
1
Midazolam
1
Etoposide
1
Dasatinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Brain Diseases
×
enzalutamide
×
Clear all
NCT04290611
2023-04-13
VENDY
Groupe Hospitalier Pitie-Salpetriere
Completed
500,000 enrolled